ImmuCell Corp (ICCC)
5.04
+0.02
(+0.40%)
USD |
NASDAQ |
Apr 22, 16:00
5.06
+0.02
(+0.40%)
After-Hours: 20:00
ImmuCell Enterprise Value: 50.06M for April 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 22, 2024 | 50.06M |
| April 19, 2024 | 49.90M |
| April 18, 2024 | 50.13M |
| April 17, 2024 | 50.13M |
| April 16, 2024 | 50.13M |
| April 15, 2024 | 50.29M |
| April 12, 2024 | 49.90M |
| April 11, 2024 | 50.75M |
| April 10, 2024 | 51.30M |
| April 09, 2024 | 51.45M |
| April 08, 2024 | 52.23M |
| April 05, 2024 | 51.06M |
| April 04, 2024 | 51.06M |
| April 03, 2024 | 51.26M |
| April 02, 2024 | 51.61M |
| April 01, 2024 | 51.37M |
| March 28, 2024 | 52.07M |
| March 27, 2024 | 51.99M |
| March 26, 2024 | 50.99M |
| March 25, 2024 | 51.68M |
| March 22, 2024 | 51.53M |
| March 21, 2024 | 50.44M |
| March 20, 2024 | 50.44M |
| March 19, 2024 | 49.44M |
| March 18, 2024 | 49.67M |
| Date | Value |
|---|---|
| March 15, 2024 | 51.68M |
| March 14, 2024 | 50.91M |
| March 13, 2024 | 50.60M |
| March 12, 2024 | 50.52M |
| March 11, 2024 | 51.49M |
| March 08, 2024 | 51.30M |
| March 07, 2024 | 51.30M |
| March 06, 2024 | 51.68M |
| March 05, 2024 | 52.07M |
| March 04, 2024 | 53.31M |
| March 01, 2024 | 51.92M |
| February 29, 2024 | 51.92M |
| February 28, 2024 | 51.45M |
| February 27, 2024 | 50.83M |
| February 26, 2024 | 51.14M |
| February 23, 2024 | 50.83M |
| February 22, 2024 | 51.30M |
| February 21, 2024 | 49.59M |
| February 20, 2024 | 50.60M |
| February 16, 2024 | 50.91M |
| February 15, 2024 | 49.91M |
| February 14, 2024 | 49.75M |
| February 13, 2024 | 50.06M |
| February 12, 2024 | 50.52M |
| February 09, 2024 | 51.06M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
28.35M
Minimum
Mar 12 2020
87.31M
Maximum
Feb 19 2021
53.33M
Average
50.13M
Median
Apr 16 2024
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.139M |
| Palatin Technologies Inc | 18.27M |
| iBio Inc | 16.07M |
| Theriva Biologics Inc | -13.17M |
| Oragenics Inc | 3.172M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.140M |
| Revenue (Quarterly) | 5.096M |
| Total Expenses (Quarterly) | 6.100M |
| EPS Diluted (Quarterly) | -0.15 |
| Gross Profit Margin (Quarterly) | 24.68% |
| Profit Margin (Quarterly) | -22.37% |
| Earnings Yield | -14.88% |
| Normalized Earnings Yield | -15.60 |